Company research
Neuronetics, Inc.
CIK 1227636Updated Sep 27, 2026
SecuritySTIM · NASDAQ · equity
Name history
Neuronetics, Inc. · through Aug 24, 2026NEURONETICS INC · through Aug 16, 2006
STIM price & chart
Loading TradingView…
NASDAQ:STIM on TradingView ↗About the company
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the Company is a leading provider of transcranial magnetic stimulation (“TMS”) treatment and, through Greenbrook TMS Inc. (“Greenbrook”), operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for major depressive disorder (“MDD”) in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) nasal spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or …
In the news
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business ↗
Recent filings
144 filing
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SCHEDULE 13G filing
S-8 filing
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SD filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 141,551,000Source | 140,903,000Source | 115,831,000Source | 116,884,000Source |
| Property, Plant and Equipment, NetUSD | 4,466,000Source | 6,242,000Source | 2,009,000Source | 1,991,000Source |
| GoodwillUSD | 23,622,000Source | 18,634,000Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 18,149,000Source | 19,606,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 28,134,000Source | 18,459,000Source | 59,677,000Source | 70,340,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 16,469,000Source | 23,355,000Source | 15,782,000Source | 13,591,000Source |
| Inventory, NetUSD | 4,327,000Source | 4,248,000Source | 8,093,000Source | 8,899,000Source |
| Assets, CurrentUSD | 61,551,000Source | 58,122,000Source | 93,793,000Source | 98,769,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,922,000Source | 6,846,000Source | 4,766,000Source | 2,174,000Source |
| Operating Lease, Right-of-Use AssetUSD | 23,560,000Source | 27,093,000Source | 2,773,000Source | 3,327,000Source |
| Other Assets, NoncurrentUSD | 1,982,000Source | 1,923,000Source | 4,430,000Source | 3,645,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 115,311,000Source | 109,104,000Source | 81,641,000Source | 59,824,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 690,000Source | 557,000Source | 291,000Source | 273,000Source |
| Retained Earnings (Accumulated Deficit)USD | -458,787,000Source | -419,789,000Source | -376,081,000Source | -345,892,000Source |
| Stockholders' Equity Attributable to ParentUSD | 22,378,000Source | 27,706,000Source | 34,190,000Source | 57,060,000Source |
| Additional Paid in Capital, Common StockUSD | 480,475,000Source | 446,938,000Source | 409,980,000Source | 402,679,000Source |
| Liabilities and EquityUSD | 141,551,000Source | 140,903,000Source | 115,831,000Source | 116,884,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 30,521,000Source | 31,265,000Source | 19,812,000Source | 33,199,000Source |
| Operating Lease, Liability, CurrentUSD | 5,561,000Source | 4,791,000Source | 845,000Source | 824,000Source |
| Accounts Payable, CurrentUSD | 10,739,000Source | 11,077,000Source | 4,752,000Source | 2,433,000Source |
| Operating Lease, Liability, NoncurrentUSD | 18,935,000Source | 22,686,000Source | 2,346,000Source | 2,967,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 3,862,000Source | 4,093,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 12,316,000Source | 12,818,000Source | 12,595,000Source | 14,837,000Source |
| Deferred Revenue, CurrentUSD | 753,000Source | 974,000Source | 1,620,000Source | 1,980,000Source |
| Deferred Revenue, NoncurrentUSD | 48,000Source | 2,000Source | 200,000Source | 829,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 65,807,000Source | 55,151,000Source | 59,283,000Source | — |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 13,125,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 65,807,000Source | 55,151,000Source | 59,283,000Source | 22,829,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -39,135,000Source | -43,727,000Source | -30,189,000Source | -37,159,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,465,000Source | 2,073,000Source | 2,006,000Source | 1,648,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,848,000Source | 5,602,000Source | 7,319,000Source | 8,746,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -3,541,000Source | 3,727,000Source | 8,831,000Source | 6,317,000Source |
| Increase (Decrease) in InventoriesUSD | 395,000Source | -3,150,000Source | 1,098,000Source | 2,587,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,750,000Source | -1,985,000Source | 2,029,000Source | -1,968,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -20,374,000Source | -30,997,000Source | -32,038,000Source | -30,739,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 2,553,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -801,000Source | -2,413,000Source | -1,322,000Source | 6,731,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 35,850,000Source | -6,808,000Source | 22,697,000Source | 207,000Source |
| Repayments of Long-term DebtUSD | — | 60,000,000Source | 1,200,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 34,134,000Source | 19,459,000Source | 59,677,000Source | 70,340,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 7,591,000Source | 6,513,000Source | 4,790,000Source | 3,543,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,848,000Source | 5,602,000Source | 7,319,000Source | 8,746,000Source |
| Amortization of Debt Issuance CostsUSD | 800,000Source | 800,000Source | 600,000Source | 700,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 824,000Source | 771,000Source | 634,000Source | 709,000Source |
| Amortization of Intangible AssetsUSD | 1,500,000Source | 100,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -72,000Source | -28,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | -4,427,000Source | — | — |
| General and Administrative ExpenseUSD | 49,702,000Source | 30,322,000Source | 25,426,000Source | 25,516,000Source |
| GoodwillUSD | 23,622,000Source | 18,634,000Source | — | — |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| InterestExpenseNonoperatingUSD | 8,415,000Source | — | — | — |
| Inventory Write-downUSD | 388,000Source | 626,000Source | 1,905,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -38,998,000Source | -43,708,000Source | -30,189,000Source | -37,159,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -137,000Source | -19,000Source | — | — |
| Operating ExpensesUSD | 103,744,000Source | 88,724,000Source | 82,259,000Source | 84,834,000Source |
| Operating Lease, ExpenseUSD | 9,500,000Source | 1,000,000Source | 800,000Source | 800,000Source |
| Operating Lease, Impairment LossUSD | 400,000Source | 600,000Source | 1,900,000Source | — |
| Operating Lease, Lease IncomeUSD | 200,000Source | 100,000Source | 200,000Source | 200,000Source |
| Other Nonoperating Income (Expense)USD | 716,000Source | 2,549,000Source | 5,789,000Source | 2,203,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 10,000,000Source | 57,479,000Source | 25,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 13,000Source | 1,000Source | 1,000Source | 298,000Source |
| Sales-type Lease, Selling Profit (Loss)USD | 107,000Source | 45,000Source | 129,000Source | 478,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 149,157,000Source | 74,890,000Source | 71,348,000Source | 65,206,000Source |
| Cost of RevenueUSD | 76,849,000Source | 20,729,000Source | 19,643,000Source | 15,483,000Source |
| Operating Income (Loss)USD | -31,436,000Source | -34,563,000Source | -30,554,000Source | -35,111,000Source |
| Other Nonoperating Income (Expense)USD | 716,000Source | 2,549,000Source | 5,789,000Source | 2,203,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -137,000Source | -19,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -38,998,000Source | -43,708,000Source | -30,189,000Source | -37,159,000Source |
| Earnings Per Share, BasicUSD per share | -0.59Source | -1.38Source | -1.05Source | -1.38Source |
| Earnings Per Share, DilutedUSD per share | -0.59Source | -1.38Source | -1.05Source | -1.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 65,951,000Source | 31,734,000Source | 28,658,000Source | 26,900,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 65,951,000Source | 31,734,000Source | 28,658,000Source | 26,900,000Source |
| Interest Expense (non-operating)USD | 8,415,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,500,000Source | 100,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,000,000Source | 2,100,000Source | 2,000,000Source | 1,600,000Source |
| General and Administrative ExpenseUSD | 49,702,000Source | 30,322,000Source | 25,426,000Source | 25,516,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Gross ProfitUSD | 72,308,000Source | 54,161,000Source | 51,705,000Source | 49,723,000Source |
| Interest ExpenseUSD | — | 7,286,000Source | 5,424,000Source | 4,251,000Source |
| Interest Expense, DebtUSD | 7,600,000Source | 6,500,000Source | 4,800,000Source | 3,600,000Source |
| Operating ExpensesUSD | 103,744,000Source | 88,724,000Source | 82,259,000Source | 84,834,000Source |
| Operating Lease, ExpenseUSD | 9,500,000Source | 1,000,000Source | 800,000Source | 800,000Source |
| Operating Lease, Lease IncomeUSD | 200,000Source | 100,000Source | 200,000Source | 200,000Source |
| Other General and Administrative ExpenseUSD | 31,512,000Source | — | — | — |
| Research and Development ExpenseUSD | 6,584,000Source | 12,771,000Source | 9,515,000Source | 9,336,000Source |
| Sales-type Lease, Selling Profit (Loss)USD | 107,000Source | 45,000Source | 129,000Source | 478,000Source |
| Selling and Marketing ExpenseUSD | 47,458,000Source | 45,631,000Source | 47,318,000Source | 49,982,000Source |
Filing attachments
d78613dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d78613dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neuronetics Reports Second Quarter 2026 Financial and Operating Results MALVERN, PA., August 11, 2026 - Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026. Se…
Read attachment ↗d78613dex992.htm · 8-K · 2026-08-11
EX-99.2 3 d78613dex992.htm EX-99.2 EX-99.2 COMPANY PRESENTATION NASDAQ: STIM August 2026 Exhibit 99.2 Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give und…
Read attachment ↗d226320dex991.htm · 8-K · 2026-07-20
EX-99.1 4 d226320dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experience ────────────────────────────────────────────────────────────────────────────────────────────────────────────── Cory Anderson promoted to Executive Vice President and General Manager, Greenbrook eff…
Read attachment ↗d139145dex991.htm · 8-K · 2026-05-05
EX-99.1 2 d139145dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neuronetics Reports First Quarter 2026 Financial and Operating Results MALVERN, PA., May 5, 2026 - Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial an…
Read attachment ↗d139145dex992.htm · 8-K · 2026-05-05
EX-99.2 3 d139145dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 COMPANY PRESENTATION NASDAQ: STIM May 2026 Transforming Lives Through NeuroHealth Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, …
Read attachment ↗d107138dex991.htm · 8-K · 2026-04-06
EX-99.1 3 d107138dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neuronetics Announces Chief Financial Officer Transition Reaffirms Fiscal Year 2026 Financial Guidance MALVERN, Pa., April 6, 2026 (GLOBE NEWSWIRE) - Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced tha…
Read attachment ↗